Faruqi & Faruqi, LLP is investigating claims on behalf of Checkpoint investors

NEW YORK, May 10, 2024 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating and reminds investors of potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT). June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

James (Josh) Wilson, Faruqi and Faruqi, LLP Securities Litigation Partner, encourages investors who have suffered losses that are greater $100,000 At Checkpoint you can contact him directly to discuss your options.

If you have suffered losses that go beyond this $100,000 Investing in Checkpoint stocks or options in between March 10, 2021 And December 15, 2023 and would like to discuss your legal rights, Call Faruqi & Faruqi Partners Josh Wilson direct at 877-247-4292 or 212-983-9330 (ext. 1310). For more information you can also click here: www.faruqilaw.com/CKPT.

Faruqi & Faruqi is a leading national securities law firm with offices in new York, Pennsylvania, California And Georgia. The company has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As described below, the complaint claims that the Company and its officers violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Checkpoint overstated its oversight and/or implementation of appropriate third-party manufacturing standards and controls; (ii) accordingly, there were one or more issues with the Company’s third-party contract manufacturing organization (“CMO”) for cosibelimab; (iii) all of the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its current form; (iv) as a result, the manufacturing, regulatory and commercial prospects of cosibelimab have been overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

At December 18, 2023Checkpoint announced in a press release that the FDA has not approved cosibelimab BLA for the treatment of patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation. Specifically, the company announced “that the (FDA) has issued a complete response letter (“CRL”) for cosibelimab (BLA) for the treatment of patients with metastatic or locally advanced disease (cSCC) who are not candidates for curative surgery and radiation The company stated that “the CRL … cites findings that emerged during a multi-sponsor inspection by Checkpoint’s third-party vendor (CMO) as approval issues that must be addressed in a resubmission.”

On this news, Checkpoint’s share price fell $1.49 per share or 44.88% to close $1.83 per share December 18, 2023.

The court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class, who is appropriate and typical of the class, and who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may request the Court to serve as lead plaintiff through counsel of their choice, or may elect to do nothing and remain an absent class member. Your ability to share in any recovery will not be affected by the decision to serve as lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information about Checkpoint’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

To find out more about the checkpoint Class action lawsuit, go for it www.faruqilaw.com/CKPT or Call Faruqi & Faruqi Partners Josh Wilson direct at 877-247-4292 or 212-983-9330 (ext. 1310).

Lawyer advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar result with respect to future matters. We welcome the opportunity to discuss your individual case. All communications will be treated confidentially.

SOURCE Faruqi & Faruqi, LLP